Fast track designation sounds amazing however in the overall scheme of events approval leading to $ (as a result of fast track) is hard to come by and most fast track approvals end up being a waste
National Library of Medicine states:
"The current success rate of a drug candidate, from the beginning of the clinical trial to receiving marketing approval, is about 10%–20%, and it has not changed during the past few decades. Therefore, pharmaceutical companies are under pressure to select one compound, among many others, with a high probability of success"
AI Overview states:
"The FDA grants fast track approvals to a significant number of new drugs, with 36% of drugs designated as Fast Track in 2021"
IMU Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)